Up-regulation of NGEF by ERK/AP1 signaling pathway in BRAFV600E-mutant thyroid cancer promotes cancer metastasis

Zhao Fu, Ye Wang, Congjun Wang, Yu Zhu, Weijia Huang, Kaitian Zheng, Shengyu Wang, Jian Yang, Junqiang ChenResearch Square 2023 · DOI

Abstract

The BRAF<sup>V600E</sup> mutation is the most frequent genetic alteration in thyroid tumors and a primary therapeutic target. However, intrinsic feedback mechanisms often limit the efficacy of BRAF-specific inhibitors. This study investigates the role of NGEF (Neuronal Guanine Nucleotide Exchange Factor) in thyroid cancer progression. Using bioinformatics and clinical validation, the researchers found that NGEF is significantly upregulated in malignant tissues and correlates with advanced TNM stages and poorer disease-free survival. Mechanistically, the BRAF<sup>V600E</sup>-mediated MAPK/ERK cascade activates the transcription factor AP-1, which directly binds to the NGEF promoter. Increased NGEF expression subsequently promotes cancer metastasis by inducing epithelial-mesenchymal transition (EMT). These findings suggest that NGEF is a critical downstream effector of BRAF<sup>V600E</sup> and a potential therapeutic target.

Introduction

Thyroid cancer incidence has risen globally over recent decades. While many patients respond well to standard treatments, those with the BRAF<sup>V600E</sup> mutation often face more aggressive disease and higher rates of metastasis. Current targeted therapies against mutant BRAF face challenges due to cellular adaptation and feedback loops. Identifying the specific downstream proteins that execute the metastatic program is essential for developing more effective treatments. This study focuses on NGEF, a protein traditionally associated with neuronal development, to determine its role in thyroid cancer spread.

Methods

The researchers utilized a multi-faceted approach to explore NGEF's role:

  • Bioinformatics: Large-scale data from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO, dataset GSE 33630) were analyzed for gene expression and clinical correlations.
  • Clinical Validation: NGEF levels were measured in 32 pairs of human thyroid cancer and adjacent normal tissues using RT-qPCR, Western blotting, and immunohistochemistry (IHC).
  • Functional Assays: Wound healing and Transwell assays were conducted in BRAF-mutant cell lines (K1 and 8305C) to assess migration and invasion.
  • Pathway Analysis: The regulatory link between BRAF, ERK, AP-1, and NGEF was confirmed using specific pathway inhibitors and dual-luciferase reporter assays.

Results

Clinical Significance and Expression Patterns

Initial bioinformatics analysis and clinical validation confirmed that NGEF mRNA and protein levels are significantly elevated in thyroid cancer compared to normal tissues. High NGEF expression was strongly associated with advanced TNM stages and significantly shorter disease-free survival (DFS) in patients.

NGEF expression levels and clinical correlation in thyroid cancer.

Regulation via the BRAF-ERK-AP1 Axis

The study established that NGEF expression is specifically enhanced in BRAF<sup>V600E</sup>-mutant thyroid cancer. The researchers demonstrated that the MAPK/ERK signaling cascade, triggered by the BRAF mutation, activates the transcription factor AP-1 (c-fos/c-jun). Dual-luciferase assays confirmed that AP-1 directly binds to the NGEF promoter, acting as the molecular bridge that "switches on" NGEF expression in response to oncogenic signaling.

NGEF Drives Metastasis through EMT

Functional experiments revealed that NGEF is a potent driver of metastasis. Knocking down NGEF in BRAF-mutant cells significantly inhibited their ability to migrate and invade. Conversely, overexpressing NGEF enhanced these behaviors. This metastatic shift was attributed to Epithelial-Mesenchymal Transition (EMT), where NGEF leads to the downregulation of epithelial markers (like E-cadherin) and the upregulation of mesenchymal markers (like Vimentin and N-cadherin), allowing cells to detach and spread.

Conclusion

This research identifies NGEF as a key mediator of metastasis in BRAF<sup>V600E</sup>-mutant thyroid cancer. By linking the ERK/AP-1 signaling pathway to NGEF-induced EMT, the study provides a clearer picture of how common genetic mutations physically drive cancer progression. NGEF represents a promising new biomarker for prognosis and a potential therapeutic target to prevent metastasis in aggressive thyroid tumors.

Summary updated

Abstract

<title>Abstract</title> <bold>Background</bold> The BRAFV600E mutation is the most frequent genetic mutation in thyroid tumors, and is therefore a key therapeutic target. However, intrinsic feedback mechanisms impact the clinical use of BRAFV600E-specific inhibitors. Further investigations into the specific roles and molecular mechanisms underlying BRAFV600E in thyroid cancer progression are required.<bold>Methods</bold> In the present study, Gene Expression Omnibus and The Cancer Genome Atlas datasets were used to identify NGEF (Neuronal Guanine Nucleotide Exchange Factor ) gene expression patterns and the corresponding clinical relevance. NGEF expression levels were determined in tissues and cells using reverse transcription-quantitative (RT-q) PCR, western blotting and immunohistochemical analyses. Moreover, potential associations between the BRAFV600E mutation and NGEF were verified using bioinformatics, RT-qPCR and western blot analysis. In vitro experiments were conducted to investigate the cytological role of NGEF. Results of the present study demonstrated that the transcription factor AP-1 (c-fos/c-jun) was upstream of NGEF by the bioinformatics, qRT-PCR, WB, and dual luciferase reporter assays.<bold>Results</bold> NGEF mRNA and protein expression levels were significantly elevated in thyroid malignant specimens, compared with adjacent non-tumor tissues. In addition, increased NGEF expression was associated with TNM stage in patients with thyroid cancer. Results of the present study also demonstrated that NGEF expression was significantly enhanced in BRAFV600E-mutant thyroid cancer, and NGEF knockdown in BRAFV600E-mutant thyroid cancer cells inhibited migration and invasion, through impacting epithelial-mesenchymal transition. On the other hand, the reverse effects were observed following NGEF overexpression. Results of the present study further demonstrated that the BRAFV600E-mediated MAPK/ERK cascade upregulated NGEF expression, and NGEF was subsequently identified as a target of AP-1.<bold>Conclusions</bold> NGEF is expressed by the ERK/AP-1 pathway in BRAFV600E-mutant thyroid cancer, and is associated with tumor metastasis. These results indicated that NGEF may exhibit potential as a therapeutic target in BRAFV600E-mutant thyroid cancer.
BibTeX
@inproceedings{fu2023up,
  author = {Zhao Fu and Ye Wang and Congjun Wang and Yu Zhu and Weijia Huang and Kaitian Zheng and Shengyu Wang and Jian Yang and Junqiang Chen},
  title = {{Up-regulation of NGEF by ERK/AP1 signaling pathway in BRAFV600E-mutant thyroid cancer promotes cancer metastasis}},
  booktitle = {Research Square},
  year = {2023},
  doi = {10.21203/rs.3.rs-2865959/v1},
}
Figure